Ahmad Hanif1, Manu Pandey1, Sumera Khan2, Kristopher Attwood3, Saby George1. 1. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 2. Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 3. Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Abstract
Introduction: Renal cell carcinoma (RCC) with sarcomatoid component carries a poor prognosis. Immune checkpoint inhibitors (CPIs) have been approved for the treatment of metastatic RCC, but their efficacy in patients with sarcomatoid component is not known. Materials and Methods: We conducted a retrospective chart review of 30 consecutive patients at our center who were treated for metastatic RCC with sarcomatoid component. Results: Ten patients were treated with CPI group while 20 patients were in No-CPI group. There were no significant differences in age, sex, race, and stage at diagnosis between the two groups. After a median follow-up of 35 months, 3 of 10 patients in CPI arm and 5 of 20 patients in No-CPI group were alive. The median overall survival was 33.8 m in immunotherapy group compared to 8.8 m in nonimmunotherapy group (p = .001). Discussion: In our experience, CPI therapy resulted in better outcomes compared to traditional therapy with molecular-targeted agents or chemotherapy in these patients.
Introduction: Renal cell carcinoma (RCC) with sarcomatoid component carries a poor prognosis. Immune checkpoint inhibitors (CPIs) have been approved for the treatment of metastatic RCC, but their efficacy in patients with sarcomatoid component is not known. Materials and Methods: We conducted a retrospective chart review of 30 consecutive patients at our center who were treated for metastatic RCC with sarcomatoid component. Results: Ten patients were treated with CPI group while 20 patients were in No-CPI group. There were no significant differences in age, sex, race, and stage at diagnosis between the two groups. After a median follow-up of 35 months, 3 of 10 patients in CPI arm and 5 of 20 patients in No-CPI group were alive. The median overall survival was 33.8 m in immunotherapy group compared to 8.8 m in nonimmunotherapy group (p = .001). Discussion: In our experience, CPI therapy resulted in better outcomes compared to traditional therapy with molecular-targeted agents or chemotherapy in these patients.
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Staehler; Sylvie Negrier; Christine Chevreau; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Sibyl Anderson; Gloria Hofilena; Minghua Shan; Carol Pena; Chetan Lathia; Ronald M Bukowski Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud Journal: Lancet Date: 2008-07-22 Impact factor: 79.321
Authors: B Escudier; J P Droz; F Rolland; M J Terrier-Lacombe; G Gravis; P Beuzeboc; B Chauvet; C Chevreau; J C Eymard; T Lesimple; Y Merrouche; S Oudard; F Priou; C Guillemare; S Gourgou; S Culine Journal: J Urol Date: 2002-09 Impact factor: 7.450
Authors: Ali Reza Golshayan; Saby George; Daniel Y Heng; Paul Elson; Laura S Wood; Tarek M Mekhail; Jorge A Garcia; Hakan Aydin; Ming Zhou; Ronald M Bukowski; Brian I Rini Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544
Authors: Dylan J Martini; Meredith R Kline; Yuan Liu; Julie M Shabto; Bradley C Carthon; Greta Anne Russler; Lauren Yantorni; Emilie Elise Hitron; Sarah Caulfield; Jamie M Goldman; Wayne B Harris; Omer Kucuk; Viraj A Master; Mehmet Asim Bilen Journal: Cancer Treat Res Commun Date: 2021-05-09
Authors: Eliezer M Van Allen; Toni K Choueiri; Ziad Bakouny; David A Braun; Sachet A Shukla; Wenting Pan; Xin Gao; Yue Hou; Abdallah Flaifel; Stephen Tang; Alice Bosma-Moody; Meng Xiao He; Natalie Vokes; Jackson Nyman; Wanling Xie; Amin H Nassar; Sarah Abou Alaiwi; Ronan Flippot; Gabrielle Bouchard; John A Steinharter; Pier Vitale Nuzzo; Miriam Ficial; Miriam Sant'Angelo; Juliet Forman; Jacob E Berchuck; Shaan Dudani; Kevin Bi; Jihye Park; Sabrina Camp; Maura Sticco-Ivins; Laure Hirsch; Sylvan C Baca; Megan Wind-Rotolo; Petra Ross-Macdonald; Maxine Sun; Gwo-Shu Mary Lee; Steven L Chang; Xiao X Wei; Bradley A McGregor; Lauren C Harshman; Giannicola Genovese; Leigh Ellis; Mark Pomerantz; Michelle S Hirsch; Matthew L Freedman; Michael B Atkins; Catherine J Wu; Thai H Ho; W Marston Linehan; David F McDermott; Daniel Y C Heng; Srinivas R Viswanathan; Sabina Signoretti Journal: Nat Commun Date: 2021-02-05 Impact factor: 14.919